Translational strategies to schizophrenia from a proteomic perspective

Translational Neuroscience

Volumn 3, Issue 3, 2012, Pages 300-302

  Martins De Souza, Daniel ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Biomarkers; Mass spectrometry; Proteome; Proteomics; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; ASTROCYTE; CEREBROSPINAL FLUID; DNA MICROARRAY; ENERGY METABOLISM; FIBROBLAST; HYPOPHYSIS; LIVER; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; OLIGODENDROGLIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PROCESSING; PROTEOMICS; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 84871449914     PISSN: 20813856     EISSN: 20816936     Source Type: Journal    
DOI: 10.2478/s13380-012-0031-z     Document Type: Article

References (28)

1. Freedman R., Schizophrenia, N. Engl. J. Med., 2003, 349, 1738-1749 (Pubitemid 37315012)
2. Brown A. S., The environment and susceptibility to schizophrenia, Prog. Neurobiol., 2011, 93, 23-58
3. Horvath S., Janka Z., Mirnics K., Analyzing schizophrenia by DNA microarrays, Biol. Psychiatry, 2011, 69, 157-162
4. Johnston-Wilson N. L., Sims C. D., Hofmann J. P., Anderson L., Shore A. D., Torrey E. F., et al., Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium, Mol. Psychiatry, 2000, 5, 142-149 (Pubitemid 30229428)
5. Martins-de-Souza D., Guest P. C., Rahmoune H., Bahn S., Proteomic approaches to unravel the complexity of schizophrenia, Expert Rev. Proteomics, 2012, 9, 97-108
6. Martins-De-Souza D., Dias-Neto E., Schmitt A., Falkai P., Gormanns P., Maccarrone G., et al., Proteome analysis of schizophrenia brain tissue, World J. Biol. Psychiatry, 2010, 11, 110-120
7. Krishnamurthy D., Harris L. W., Levin Y., Koutroukides T. A., Rahmoune H., Pietsch S., et al., Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects, World J. Biol. Psychiatry, 2012, [Epub ahead of print]
8. Huang J. T., Leweke F. M., Oxley D., Wang L., Harris N., Koethe D., et al., Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis, PLoS Med., 2006, 3, e428
9. Martins-De-Souza D., Wobrock T., Zerr I., Schmitt A., Gawinecka J., Schneider-Axmann T., et al., Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls, World J. Biol. Psychiatry, 2010, 11, 719-728
10. Prabakaran S., Wengenroth M., Lockstone H. E., Lilley K., Leweke F. M., Bahn S., 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia, J. Proteome Res., 2007, 6, 141-149 (Pubitemid 46173666)
11. Herberth M., Koethe D., Cheng T. M., Krzyszton N. D., Schoeffmann S., Guest P. C., et al., Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients, Mol. Psychiatry, 2011, 16, 848-859
12. Wang L., Lockstone H. E., Guest P. C., Levin Y., Palotás A., Pietsch S., et al., Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia, J. Proteome Res., 2010, 9, 521-527
13. Guest P. C., Wang L., Harris L. W., Burling K., Levin Y., Ernst A., et al., Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients, Mol. Psychiatry, 2010, 15, 118-119
14. Levin Y., Wang L., Schwarz E., Koethe D., Leweke F. M., Bahn S., Global proteomic profiling reveals altered proteomic signature in schizophrenia serum, Mol. Psychiatry, 2010, 15, 1088-1100
15. Schwarz E., Izmailov R., Spain M., Barnes A., Mapes J. P., Guest P. C., et al., Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia, Biomark. Insights, 2010, 5, 39-47
16. Schwarz E., Guest P. C., Rahmoune H., Harris L. W., Wang L., Leweke F. M., et al., Identification of a biological signature for schizophrenia in serum, Mol. Psychiatry, 2012, 17, 494-502
17. Bahn S., Noll R., Barnes A., Schwarz E., Guest P. C., Challenges of introducing new biomarker products for neuropsychiatric disorders into the market, Int. Rev. Neurobiol., 2011, 101, 299-327
18. Ji B., La Y., Gao L., Zhu H., Tian N., Zhang M., et al., A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications, J. Proteome Res., 2009, 8, 3633-3641
19. Chan M. K., Tsang T. M., Harris L. W., Guest P. C., Holmes E., Bahn S., Evidence for disease and antipsychotic medication effects in postmortem brain from schizophrenia patients, Mol. Psychiatry, 2011, 16, 1189-1202
20. Ahmed E. U., Ahmed S., Ukai W., Matsumoto I., Kemp A., McGregor I. S., et al., Antipsychotic induced alteration of growth and proteome of rat neural stem cells, Neurochem. Res., 2012, 37, 1649-1659
21. Gottschalk M. G., Sarnyai Z., Guest P. C., Harris L. W., Bahn, S., Translational neuropsychiatry of genetic and neurodevelopmental animal models of schizophrenia, Rev. Psiquiatr. Clin., 2012, in press
22. Yanagi M., Southcott S., Lister J., Tamminga C. A., Animal models of schizophrenia emphasizing construct validity, Prog. Mol. Biol. Transl. Sci., 2012, 105, 411-444
23. Martins-de-Souza D., Alsaif M., Ernst A., Harris L. W., Aerts N., Lenaerts I., et al., The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia, BMC Res. Notes, 2012, 5, 146
24. Paulson L., Martin P., Nilsson C. L., Ljung E., Westman-Brinkmalm A., Blennow K., et al., Comparative proteome analysis of thalamus in MK- 801-treated rats, Proteomics, 2004, 4, 819-825 (Pubitemid 38339159)
25. Martins-de-Souza D., Lebar M., Turck C. W., Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia, Eur. Arch. Psychiatry Clin. Neurosci., 2011, 261, 217-228
26. Steiner J., Sarnyai Z., Westphal S., Gos T., Bernstein H. G., Bogerts B., et al., Protective effects of haloperidol and clozapine on energydeprived OLN-93 oligodendrocytes, Eur. Arch. Psychiatry Clin. Neurosci., 2011, 261, 477-482
27. Bernstein H. G., Steiner J., Bogerts B., Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy, Expert Rev. Neurother., 2009, 9, 1059-1071
28. Martins-de-Souza D., Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia, J. Psychiatr. Res., 2010, 44, 149-156